When compared to untreated control cells, Western blot data showed that FKB treatment (0–10 μg/mL, 24 h) dose-dependently suppressed the expressions of BRAF and its downstream p-ERK1/2 proteins in BRAF-expressing melanoma A375 cells (Figure 1F). The gene discussed is BRAF; the disease is melanoma.